S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
AI Stock Caught Trading Under Secret Name (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
AI Stock Caught Trading Under Secret Name (Ad)
5 Economic Trends That Will Drive The Market In Q4
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Elon Did It Again: This Could be Bigger than Tesla (Ad)
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
Inflation is Why a Soft Landing is Bad for the Economy
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
AI Stock Caught Trading Under Secret Name (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
AI Stock Caught Trading Under Secret Name (Ad)
5 Economic Trends That Will Drive The Market In Q4
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Elon Did It Again: This Could be Bigger than Tesla (Ad)
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
Inflation is Why a Soft Landing is Bad for the Economy
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
AI Stock Caught Trading Under Secret Name (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
AI Stock Caught Trading Under Secret Name (Ad)
5 Economic Trends That Will Drive The Market In Q4
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Elon Did It Again: This Could be Bigger than Tesla (Ad)
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
Inflation is Why a Soft Landing is Bad for the Economy
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
AI Stock Caught Trading Under Secret Name (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
AI Stock Caught Trading Under Secret Name (Ad)
5 Economic Trends That Will Drive The Market In Q4
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Elon Did It Again: This Could be Bigger than Tesla (Ad)
South Asia is expected to grow by nearly 6% this year, making it the world's fastest-growing region
Inflation is Why a Soft Landing is Bad for the Economy
NASDAQ:KRYS

Krystal Biotech (KRYS) Stock Forecast, Price & News

$111.99
+0.42 (+0.38%)
(As of 10/3/2023 ET)
Compare
Today's Range
$110.13
$112.63
50-Day Range
$108.51
$130.22
52-Week Range
$61.11
$132.68
Volume
266,677 shs
Average Volume
326,948 shs
Market Capitalization
$3.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$137.57

Krystal Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
22.8% Upside
$137.57 Price Target
Short Interest
Bearish
5.68% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.44mentions of Krystal Biotech in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$3.18 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.08) to ($1.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

681st out of 966 stocks

Biological Products, Except Diagnostic Industry

92nd out of 144 stocks


KRYS stock logo

About Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

KRYS Price History

KRYS Stock News Headlines

Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Update
The #1 Energy Passive Income Investment for 2023
It's not a stock, bond or private company... But this little-known alternative investment could hand you BIG MONTHLY INCOME from the oil and gas surge in 2023.
Krystal Biotech (NASDAQ:KRYS) Stock Price Down 2.3%
Krystal Biotech wins FDA nod to run trial for gene therapy
The #1 Energy Passive Income Investment for 2023
It's not a stock, bond or private company... But this little-known alternative investment could hand you BIG MONTHLY INCOME from the oil and gas surge in 2023.
Krystal Biotech Announces FDA Clearance Of IND For KB408
Krystal Biotech CEO sells shares worth $6.3M
5 Analysts Have This to Say About Krystal Biotech
Krystal Biotech: FDA Grants Orphan Drug Designation For KB408
Krystal Biotech sells priority review voucher for $100M
See More Headlines
Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Company Calendar

Last Earnings
8/07/2023
Today
10/04/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRYS
Fax
N/A
Employees
210
Year Founded
2017

Price Target and Rating

Average Stock Price Forecast
$137.57
High Stock Price Forecast
$154.00
Low Stock Price Forecast
$118.00
Forecasted Upside/Downside
+22.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-139,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$20.28 per share

Miscellaneous

Free Float
23,235,000
Market Cap
$3.13 billion
Optionable
Not Optionable
Beta
0.85

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Krish S. Krishnan M.B.A. (Age 58)
    M.S., Founder, Chairman, Pres & CEO
    Comp: $1.07M
  • Ms. Suma M. KrishnanMs. Suma M. Krishnan (Age 58)
    Founder, COO, Pres of R&D and Director
    Comp: $789.92k
  • Ms. Kathryn A. Romano (Age 41)
    Exec. VP & Chief Accounting Officer
    Comp: $528.87k
  • Ms. Meg Dodge
    VP of Investor Relations & Corp. Communications
  • Mr. John Karakkal
    VP of North American Sales & Marketing
  • Mr. Josh Suskin
    Director of HR & Operations
  • Dr. Hubert C. Chen M.D. (Age 54)
    Sr. VP of Clinical Devel.
  • Mr. Laurent Goux
    Sr. VP & GM of Europe
  • Mr. Ram Kamineni
    Sr. VP of CMC & Technical Operations
  • Mr. David Chien
    Sr. VP of Clinical Devel.













KRYS Stock - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings
or view top-rated stocks.

What is Krystal Biotech's stock price forecast for 2023?

7 Wall Street analysts have issued 1 year target prices for Krystal Biotech's shares. Their KRYS share price forecasts range from $118.00 to $154.00. On average, they anticipate the company's share price to reach $137.57 in the next twelve months. This suggests a possible upside of 22.8% from the stock's current price.
View analysts price targets for KRYS
or view top-rated stocks among Wall Street analysts.

How have KRYS shares performed in 2023?

Krystal Biotech's stock was trading at $79.22 at the beginning of 2023. Since then, KRYS shares have increased by 41.4% and is now trading at $111.99.
View the best growth stocks for 2023 here
.

Are investors shorting Krystal Biotech?

Krystal Biotech saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,590,000 shares, an increase of 6.0% from the August 31st total of 1,500,000 shares. Based on an average trading volume of 268,500 shares, the short-interest ratio is presently 5.9 days.
View Krystal Biotech's Short Interest
.

When is Krystal Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our KRYS earnings forecast
.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) announced its earnings results on Monday, August, 7th. The company reported ($1.25) earnings per share for the quarter, beating analysts' consensus estimates of ($1.27) by $0.02.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $111.99.

How much money does Krystal Biotech make?

Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $3.13 billion. The company earns $-139,980,000.00 in net income (profit) each year or ($5.43) on an earnings per share basis.

How many employees does Krystal Biotech have?

The company employs 210 workers across the globe.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com.

This page (NASDAQ:KRYS) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -